Corcept Therapeutics Incorporated Financial Statements (CORT)
|
|
|
|
Report date
|
|
|
23.02.2021 |
15.11.2021 |
15.02.2022 |
28.02.2023 |
15.02.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
353.9 |
353.9 |
366.0 |
401.9 |
482.4 |
|
628.6 |
|
Operating Income, bln rub |
|
|
128.2 |
128.2 |
124.5 |
112.6 |
107.3 |
|
143.4 |
|
EBITDA, bln rub |
? |
|
128.2 |
130.4 |
124.5 |
112.6 |
108.3 |
|
144.6 |
|
Net profit, bln rub |
? |
|
106.0 |
106.0 |
112.5 |
101.4 |
106.1 |
|
141.3 |
|
|
OCF, bln rub |
? |
|
152.0 |
152.0 |
167.9 |
120.3 |
127.0 |
|
144.7 |
|
CAPEX, bln rub |
? |
|
1.24 |
1.24 |
0.469 |
0.413 |
0.139 |
|
2.05 |
|
FCF, bln rub |
? |
|
150.7 |
150.7 |
167.4 |
119.9 |
126.9 |
|
142.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
220.1 |
220.1 |
236.2 |
283.8 |
368.6 |
|
475.4 |
|
Cost of production, bln rub |
|
|
5.58 |
5.58 |
5.28 |
5.39 |
6.48 |
|
9.80 |
|
R&D, bln rub |
|
|
114.8 |
114.8 |
113.9 |
131.0 |
184.4 |
|
231.3 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
3.56 |
0.000 |
|
3.58 |
|
|
Assets, bln rub |
|
|
571.7 |
571.7 |
423.8 |
583.4 |
621.5 |
|
784.3 |
|
Net Assets, bln rub |
? |
|
523.3 |
523.3 |
375.8 |
501.8 |
506.7 |
|
638.8 |
|
Debt, bln rub |
|
|
2.55 |
2.55 |
0.526 |
1.14 |
0.151 |
|
6.79 |
|
Cash, bln rub |
|
|
476.9 |
476.9 |
335.8 |
436.6 |
368.2 |
|
380.3 |
|
Net debt, bln rub |
|
|
-474.3 |
-474.3 |
-335.3 |
-435.5 |
-368.1 |
|
-373.5 |
|
|
Ordinary share price, rub |
|
|
26.2 |
26.2 |
19.8 |
20.3 |
32.5 |
|
25.3 |
|
Number of ordinary shares, mln |
|
|
115.4 |
115.4 |
115.7 |
106.8 |
103.6 |
|
103.4 |
|
|
Market cap, bln rub |
|
|
3 019 |
3 019 |
2 290 |
2 169 |
3 364 |
|
2 614 |
|
EV, bln rub |
? |
|
2 545 |
2 545 |
1 955 |
1 733 |
2 996 |
|
2 241 |
|
Book value, bln rub |
|
|
523 |
523 |
376 |
502 |
507 |
|
639 |
|
|
EPS, rub |
? |
|
0.92 |
0.92 |
0.97 |
0.95 |
1.02 |
|
1.37 |
|
FCF/share, rub |
|
|
1.31 |
1.31 |
1.45 |
1.12 |
1.23 |
|
1.38 |
|
BV/share, rub |
|
|
4.53 |
4.53 |
3.25 |
4.70 |
4.89 |
|
6.18 |
|
|
EBITDA margin, % |
? |
|
36.2% |
36.9% |
34.0% |
28.0% |
22.5% |
|
23.0% |
|
Net margin, % |
? |
|
30.0% |
30.0% |
30.7% |
25.2% |
22.0% |
|
22.5% |
|
FCF yield, % |
? |
|
4.99% |
4.99% |
7.31% |
5.53% |
3.77% |
|
5.45% |
|
ROE, % |
? |
|
20.3% |
20.3% |
29.9% |
20.2% |
20.9% |
|
22.1% |
|
ROA, % |
? |
|
18.5% |
18.5% |
26.6% |
17.4% |
17.1% |
|
18.0% |
|
|
P/E |
? |
|
28.5 |
28.5 |
20.4 |
21.4 |
31.7 |
|
18.5 |
|
P/FCF |
|
|
20.0 |
20.0 |
13.7 |
18.1 |
26.5 |
|
18.3 |
|
P/S |
? |
|
8.53 |
8.53 |
6.26 |
5.40 |
6.97 |
|
4.16 |
|
P/BV |
? |
|
5.77 |
5.77 |
6.09 |
4.32 |
6.64 |
|
4.09 |
|
EV/EBITDA |
? |
|
19.9 |
19.5 |
15.7 |
15.4 |
27.7 |
|
15.5 |
|
Debt/EBITDA |
|
|
-3.70 |
-3.64 |
-2.69 |
-3.87 |
-3.40 |
|
-2.58 |
|
|
R&D/CAPEX, % |
|
|
9 270% |
9 270% |
24 278% |
31 717% |
132 628% |
|
11 277% |
|
|
CAPEX/Revenue, % |
|
|
0.35% |
0.35% |
0.13% |
0.10% |
0.03% |
|
0.33% |
|
| Corcept Therapeutics Incorporated shareholders |
